Form 4: Replimune Group CFO Emily Hill Reports Stock Transactions

Emily Hill, CFO of Replimune Group, reports acquisition of stock options and restricted stock units.

Summary

• On April 1, 2024, Emily Hill, the Chief Financial Officer of Replimune Group, Inc., acquired 80,000 employee stock options at an exercise price of $7.73, vesting over four years.
• Hill also acquired 26,665 shares of common stock issuable upon settlement of restricted stock units (RSUs) at a price of $0.
• These RSUs will vest over four years, starting May 15, 2025.
• Following these transactions, Hill directly owns 109,995 shares of Replimune Group common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reflects standard executive compensation practices. The transactions themselves don't necessarily indicate a positive or negative outlook, but rather are part of a pre-determined compensation plan.

Positives

• The acquisition of stock options and RSUs by the CFO signals confidence in the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices for executives in publicly traded companies, particularly in the biotechnology industry.
• Vesting schedules of four years are also typical to incentivize long-term commitment.

Stakeholder Impact

• The transactions have a minor positive impact on stakeholders as they align the CFO's interests with those of the shareholders.

Key Dates